ArticleBMC pharmacology & toxicology2026
Complexed rifampicin with iron mitigates doxorubicin-induced nephrotoxicity.
Article in BMC pharmacology & toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundKidney disease represents a significant global health challenge that can lead to serious health complications. The chemotherapeutic agent 'doxorubicin' has nephrotoxic effects as an adverse effect. Ongoing research is focused on finding protective agents that can alleviate doxorubicin's adverse effects and enhance treatment results. Recently, an iron-rifampicin complex has been developed, showing promising anticancer activity with improved safety compared to a conventional drug. This study aimed to evaluate the potential protective effects of this iron-rifampicin complex, which has not been previously explored, against doxorubicin-induced nephrotoxicity in mice.
methodsSix groups of sixty male albino mice were used: Control, Nephrotoxicity (Neph), Neph+low dose of iron-rifampicin complex (0.071 mg iron-rifampicin complex/kg), Neph+high dose of iron-rifampicin complex (0.107 mg iron-rifampicin complex/kg), Complex control in high dose (0.107 mg iron-rifampicin complex/kg), and Vehicle control. The following parameters were evaluated: body weight, kidney weight, kidney index, creatinine, urea, uric acid, sodium, potassium, calcium, phosphorus, malondialdehyde, nitric oxide, reduced glutathione, catalase, superoxide dismutase, glutathione peroxidase, and vascular endothelial growth factor (VEGF), along with kidney histopathology.
resultsDoxorubicin-induced nephrotoxicity led to a significant reduction (p < 0.001) in body weight, kidney weight, kidney index, antioxidants, and VEGF, while increasing (p < 0.001) minerals, malondialdehyde, nitric oxide, creatinine, urea, and uric acid, alongside worsened kidney architecture. The iron-rifampicin complex improved all these parameters (p < 0.05), moving them closer to normal levels, particularly at the lower dosage, mainly by reducing oxidative stress and preserving VEGF.
conclusionIn conclusion, we propose the iron-rifampicin complex as a potential candidate for nephroprotection against doxorubicin-induced nephrotoxicity, subject to further validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.